宏源药业(301246.SZ)：第三季度净利润同比上升1316.05%
Hubei Hongyuan Pharmaceutical Technology Hubei Hongyuan Pharmaceutical Technology (SZ:301246) Ge Long Hui A P P·2025-10-22 08:49

Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) reported a year-on-year increase in revenue and a significant rise in net profit for Q3 2025, indicating strong financial performance despite a negative adjusted net profit [1] Financial Performance - The company's operating revenue for Q3 2025 reached 435 million yuan, representing a year-on-year increase of 2.45% [1] - The net profit attributable to shareholders was 4.71 million yuan, showing a substantial year-on-year increase of 1316.05% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -2.81 million yuan, indicating a loss [1]